Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
19d
- Published
- Collected
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
overfeed.news indexes and links. We publish a short excerpt — the full article stays at TechCrunch AI.
More from TechCrunch AI
Log in to follow this source
Meta releases its first frontier model, Muse Wonder
Meta's Superintelligence Lab released a pair of new state-of-the-art models on Monday, Muse Wonder and Muse Wonder Full, the company's first attempt at a frontier…
WindBorne wins a hefty US Air Force contract for its balloon data
A Silicon Valley startup that uses weather balloons and AI to predict the weather won a US military contract worth almost $50 million.
Honeyjar offers AI tools to improve PR and comms at every company
Journalists, entrepreneurs, and even some public relations professionals will tell you that the PR process is broken. But could AI actually make things better?
Microsoft president says UK is best placed to drive AI regulation
Microsoft President Brad Smith calls for urgent AI regulation, saying milk and washing machines have more oversight than AI companies.